Want to see IMUX full AI Analyst Report?
IMUX Stock Chart & Stats
$1.00
-$0.01(-1.34%)
At close: 4:00 PM EST
$1.00
-$0.01(-1.34%)
Day’s Range― - ―
52-Week Range$5.06 - $15.84
Previous CloseN/A
Volume261.21K
Average Volume (3M)241.63K
Market Cap
$201.73M
Enterprise Value-$46.07M
Total Cash (Recent Filing)$186.63M
Total Debt (Recent Filing)$421.00K
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Aug 06, 2026EPS Estimate
-1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.98
Shares Outstanding13,621,483
10 Day Avg. Volume211,538
30 Day Avg. Volume241,626
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-12.46
Price to Sales (P/S)0.00
P/FCF Ratio-0.97
Enterprise Value/Market Cap-0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.40K
Enterprise Value/Ebitda0.44
Forecast
1Y Price Target
$29.80Price Target Upside2880.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-4.53
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Favorable Phase 2 CALLIPER Efficacy And Safety SignalsRobust phase 2 CALLIPER signals, including favorable post-hoc efficacy on a unified disability endpoint and placebo-comparable safety in 467 patients, support a credible pathway into phase 3/registrational programs. These durable clinical signals improve the probability of successful late-stage development and future commercial differentiation in MS.
Strengthened Commercial And Regulatory Leadership TeamHiring experienced industry leaders with proven MS commercialization and regulatory track records materially improves execution capacity. Leadership with launch and global approval experience raises the company’s ability to design registrational programs, engage regulators, and ultimately commercialize vidofludimus, reducing execution risk over the medium term.
Low Financial Leverage Reduces Bankruptcy RiskMinimal debt gives the company financial flexibility to prioritize R&D and trial programs without interest burden. Low leverage preserves optionality for structured financings or partnerships and reduces near-term solvency risk while management executes late-stage development and potential commercialization strategies.
Bears Say
Persistent Pre-revenue Cash BurnThe company remains pre-revenue with sustained large operating losses and negative free cash flow, generating durable funding pressure. Continued cash burn necessitates periodic capital raises or partnerships, which can constrain strategic choices and impose timing risk on development programs over the next 2–6 months and beyond.
Dilution Risk And Equity VolatilityExpansion of the equity incentive pool, coupled with prior balance sheet volatility and a history of financing-driven equity moves, signals meaningful dilution risk for existing holders. Recurrent equity issuance to fund R&D can erode ownership and complicate long-term returns absent a clear commercialization milestone.
Clinical And Regulatory Execution Risk Remains MaterialDespite positive early data, success depends on upcoming pivotal phase 3 readouts and regulatory review. Clinical trial outcomes, potential safety signals in larger populations, and competitive MS landscape create lasting binary risks that determine whether the company can transition from development to sustainable commercial revenue.
Immunic News
IMUX FAQ
What was Immunic, Inc.’s price range in the past 12 months?
Immunic, Inc. lowest stock price was $5.06 and its highest was $15.84 in the past 12 months.
What is Immunic, Inc.’s market cap?
Immunic, Inc.’s market cap is $201.73M.
When is Immunic, Inc.’s upcoming earnings report date?
Immunic, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 35 days.
How were Immunic, Inc.’s earnings last quarter?
Immunic, Inc. released its earnings results on May 13, 2026. The company reported -$1.08 earnings per share for the quarter, missing the consensus estimate of -$0.688 by -$0.392.
Is Immunic, Inc. overvalued?
According to Wall Street analysts Immunic, Inc.’s price is currently Undervalued.
Does Immunic, Inc. pay dividends?
Immunic, Inc. does not currently pay dividends.
What is Immunic, Inc.’s EPS estimate?
Immunic, Inc.’s EPS estimate is -1.18.
How many shares outstanding does Immunic, Inc. have?
Immunic, Inc. has 13,621,483 shares outstanding.
What happened to Immunic, Inc.’s price movement after its last earnings report?
Immunic, Inc. reported an EPS of -$1.08 in its last earnings report, missing expectations of -$0.688. Following the earnings report the stock price went up 8.824%.
Which hedge fund is a major shareholder of Immunic, Inc.?
Currently, no hedge funds are holding shares in IMUX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.80 (2880.00% Upside)
$29.80 (2880.00% Upside)
Blogger Sentiment
Bullish
IMUX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 100.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
120.35%
12-Months-Change
Fundamentals
Return on Equity
-220.75%
Trailing 12-Months
Asset Growth
824.89%
Trailing 12-Months
Company Description
Immunic, Inc.
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
IMUX Stock 12 Month Forecast
Average Price Target
$29.80
▲(2880.00% Upside)
Technical Analysis
aTyr Pharma
―
vTv Therapeutics
―
NRX Pharmaceuticals
―
Equillium
―
Werewolf Therapeutics
―
Ownership Overview
9.28% Insiders
8.49% Mutual Funds
<0.01% Other Institutional Investors
77.68% Public Companies and Individual Investors